Oral presentation: "High antiviral activity of the HBV core inhibitor NVR 3-778 in the humanized UPA/SCID mouse model"
Poster
presentation: "Effect of the combination of the HBV core inhibitor NVR
3-778 with nucleoside analogs or other HBV core inhibitors on the
inhibition of HBV DNA replication in HepG2.2.15 cells"
DOYLESTOWN, Pa., April 27, 2015
/PRNewswire/ -- Novira Therapeutics, Inc., a privately held,
clinical-stage biopharmaceutical company developing novel therapies for
curative treatment of chronic hepatitis B virus (HBV) infection, today
announced the presentation of preclinical antiviral data for its lead
HBV core inhibitor candidate, NVR 3-778, at the 2015 annual meeting of
the European Association for the Study of the Liver (EASL) in Vienna, Austria.
The
antiviral activity of NVR 3-778 from studies performed in a humanized
UPA/SCID mouse model was described in an oral presentation. As
monotherapy given for a six week duration, NVR 3-778 showed HBV DNA
suppression efficacy superior to pegylated interferon (PEG-IFN) and
similar to that of the widely prescribed nucleoside analog entecavir.
All mice responded to treatment and there was no evidence for drug
resistance. The highest efficacy was observed in mice that received NVR
3-778 in combination with PEG-IFN, where all treated mice (n=11) reduced
serum HBV DNA below the limit of quantitation.
In
a poster session, Novira presented results from the combination of NVR
3-778 with nucleoside analogs lamivudine, tenofovir or entecavir in a
cell-based model. These data showed additive and synergistic antiviral
activity without cytotoxicity. NVR 3-778 also showed additive antiviral
activity in combination with an HBV core inhibitor from another chemical
class.
"The
apparent synergy of NVR 3-778 in combination with PEG-IFN is very
encouraging. This is the first time that we have seen a treatment with
higher DNA suppression efficacy than entecavir in a humanized mouse
model," said Klaus Klumpp,
Ph.D., Novira's VP of Discovery and Biology. "Having access to a new
class of Direct Acting Antivirals, or DAAs, enables the clinical testing
of combination treatments that may significantly intensify the
suppression of HBV production in the liver. Highly potent DAA
combination treatment may be able to reduce the rate of new hepatocyte
infection below that of infected hepatocyte clearance in HBV infected
patients and may thereby lead to a clinically-relevant improvement in
functional cure rates."
About NVR 3-778
NVR
3-778 is a small molecule, direct acting antiviral, for oral
administration in patients with Chronic Hepatitis B (CHB) that inhibits
the HBV core or capsid protein. HBV core is a novel and promising drug
target with multiple activities required for viral replication and
persistence. Inhibition of the HBV core protein function by NVR 3-778
offers the potential for more efficient suppression of virus production
and replication, leading to improved durable viral suppression and
functional cure rates. NVR 3-778 completed a Phase 1a clinical trial in
2014 and is currently enrolling a Phase 1b clinical trial.
About Novira Therapeutics
Novira
Therapeutics, Inc., is a privately held biopharmaceutical company
focused on discovery and development of first-in-class antiviral drugs
for the treatment of chronic HBV infection (CHB), a global disease with a
high level of unmet medical need. The company is employing innovative
chemistry and biology technologies to discover small molecule inhibitors
of the HBV core or capsid protein as well as other drugs with novel
mode of action. The company's novel antivirals will offer the potential
to address the limitations of current CHB therapies when used either as
mono-therapy or in combination with existing standards of care.
Labels: EASL 2015, Novira, NVR 3-778